Trial Profile
Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 19 Jan 2018 Status changed from completed to active, no longer recruiting.
- 18 Oct 2017 Status changed from active, no longer recruiting to completed.